Required Reading:

Eon van der, M. S., & Bredenkamp, J. (2013). Originator and generic medicine: Pricing and market share. International Journal of Pharmaceutical and Healthcare Marketing, 7(2), 104-119.
Gandjour, A. (2013). Reference pricing and price negotiations for innovative new drugs: Viable policies in the long term? PharmacoEconomics, 31(1), 11-4.

Jones, J.D. (2003). Developing an effective generic prescription drug program. Benefits Quarterly, 19(1): 14-18.

Kaló, Z., Annemans, L., & Garrison, L. P. (2013). Differential pricing of new pharmaceuticals in lower income European countries. Expert Review of Pharmacoeconomics & Outcomes Research, 13(6), 735-41.

Kramer, D. B., & Kesselheim, Aaron S,. (2013). The medical device excise tax — over before it begins? The New England Journal of Medicine, 368(19), 1767-9.

Monasterio, E., & Gleeson, D. (2014). Pharmaceutical industry behaviour and the trans pacific partnership agreement. The New Zealand Medical Journal (Online), 127(1389), 6-12.

Sorenson, C., Drummond, M., & Burns, L. R. (2013). Evolving reimbursement and pricing policies for devices in europe and the united states should encourage greater value. Health Affairs, 32(4), 788-96.

Sussex, J., Towse, A., & Devlin, N. (2013). Operationalizing value-based pricing of medicines: A taxonomy of approaches. PharmacoEconomics, 31(1), 1-10.

Wu, J., Xu, J., Liu, G., & Wu, J. (2014). Pharmaceutical pricing: An empirical study of market competition in Chinese hospitals. PharmacoEconomics, 32(3), 293-303.

Assignment:

1. Describe a Banner University of Arizona Medical Center (Tucson Arizona) pricing strategy for one of its services or products (e.g., a pharmaceutical drug or a medical device).

2. Explain how costs would be taken into account when formulating that pricing strategy.